Clinical Trials Logo

Methemoglobinemia, Acquired clinical trials

View clinical trials related to Methemoglobinemia, Acquired.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03542760 Completed - Methemoglobinemia Clinical Trials

Acquired Methemoglobinemia Observational Registry

metHb
Start date: May 31, 2018
Phase:
Study type: Observational [Patient Registry]

This prospective, observational registry aims to collect real-world data regarding the safety and efficacy of ProvayBlue® (methylene blue 0.5%) used according to normal standard of care for the treatment of acquired methemoglobinemia. Methylene blue has been used for decades as a rescue medication for the treatment of methemoglobinemia, a rare and potentially life-threatening condition in which elevated levels of methemoglobin impede the delivery of oxygen from blood to body tissues. However, consistent prospective data about the safety and efficacy of this medication are sparse, simply because of the rarity of the disorder. ProvayBlue® received accelerated FDA approval for treatment of acquired methemoglobinemia in 2016. This large, prospective, multi-center observational registry has been initiated to gain more information on the use of methylene blue in the treatment of acquired methemoglobinemia.